EUVIMEDEUVIMED entdecken
Open Access

The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia

Yaroslau Compta, Laura Parkkinen, Peter Kempster, Mariana Selikhova, Tammaryn Lashley, Janice L Holton, Andrew J Lees, Tamas Revesz

Neurodegenerative Diseases · 2014 · 13 (2-3) · 154-156

DOI: 10.1159/000354670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurodegenerative Diseases, online erschienen am 11.09.2013. Verfasst von Yaroslau Compta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED, Hospital Clínic, Barcelona, Spain. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Parkinson's UK, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dementia is one of the milestones of advanced Parkinson's disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications.

Objective

The aim of this study was to review the relative importance of Lewy-related α-synuclein and Alzheimer's tau and amyloid-β (Aβ) pathologies in disease progression and dementia in PD.

Methods

We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts.

Results

Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical Aβ burden determining a faster progression to dementia.

Conclusion

The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between α-synuclein, tau and Aβ and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesBrainDementiaDisease ProgressionHumansParkinson DiseaseRetrospective Studiesalpha-Synucleintau Proteins

Substanzen

Amyloid beta-Peptidesalpha-Synucleintau Proteins

Autor:innen und Institutionen

  • Parkinson Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED, Hospital Clínic, Barcelona, Spain.

Förderung

  • Wellcome Trust
  • Parkinson's UK
  • Medical Research Council

Zitieren

APA

Compta, Y., Parkkinen, L., Kempster, P., Selikhova, M., Lashley, T., Holton, J. L., Lees, A. J., & Revesz, T. (2014). The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. Neurodegenerative Diseases, 13(2-3), 154-156. https://doi.org/10.1159/000354670

Vancouver

Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL, et al. The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. Neurodegenerative Diseases. 2014;13(2-3):154-156. doi:10.1159/000354670

BibTeX
@article{Compta2014,
  author = {Compta, Yaroslau and Parkkinen, Laura and Kempster, Peter and Selikhova, Mariana and Lashley, Tammaryn and Holton, Janice L and Lees, Andrew J and Revesz, Tamas},
  title = {The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia},
  journal = {Neurodegenerative Diseases},
  year = {2014},
  volume = {13},
  number = {2-3},
  pages = {154--156},
  doi = {10.1159/000354670}
}
Kostenlos starten →